G
Gino Salituro
Researcher at Merck & Co.
Publications - 67
Citations - 2304
Gino Salituro is an academic researcher from Merck & Co.. The author has contributed to research in topics: Insulin & Insulin receptor. The author has an hindex of 23, co-authored 66 publications receiving 2080 citations.
Papers
More filters
Journal ArticleDOI
Discovery of a small molecule insulin mimetic with antidiabetic activity in mice.
Bei Zhang,Gino Salituro,Deborah Szalkowski,Zhihua Li,Yan Zhang,Inmaculada Royo,Dolores Vilella,Maria Teresa Diez,Fernando Pelaez,Caroline Ruby,Richard L. Kendall,Xianzhi Mao,Patrick R. Griffin,Jimmy R. Calaycay,Juleen R. Zierath,James V. Heck,Roy G. Smith,David E. Moller +17 more
TL;DR: The discovery of a nonpeptidyl fungal metabolite (L-783,281) that acted as an insulin mimetic in several biochemical and cellular assays demonstrates the feasibility of discovering novel insulin receptor activators that may lead to new therapies for diabetes.
Journal ArticleDOI
Small molecule insulin mimetics reduce food intake and body weight and prevent development of obesity
Ellen L. Air,Mathias Z. Strowski,Stephen C. Benoit,Stacey Conarello,Gino Salituro,Xiao-Ming Guan,Kun Liu,Stephen C. Woods,Bei B. Zhang +8 more
TL;DR: Insulin mimetics have a unique advantage over insulin in the control of body weight and hold potential as a novel anti-obesity treatment.
Journal ArticleDOI
Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice.
Carina P. Tan,Yue Feng,Yun Ping Zhou,George J. Eiermann,Aleksandr Petrov,Changyou Zhou,Songnian Lin,Gino Salituro,Peter T. Meinke,Ralph T. Mosley,Taro E. Akiyama,Monica Einstein,Sanjeev Kumar,Joel P. Berger,Sander G. Mills,Nancy A. Thornberry,Lihu Yang,Andrew D. Howard +17 more
TL;DR: GPR40 does not mediate the chronic toxic effects of FFAs on islet function, and pharmacological activation of GPR40 may potentiate GDIS in humans and be beneficial for overall glucose control in patients with type 2 diabetes.
Journal ArticleDOI
Omarigliptin (MK-3102): A Novel Long-Acting DPP-4 Inhibitor for Once-Weekly Treatment of Type 2 Diabetes.
Tesfaye Biftu,Ranabir SinhaRoy,Ping Chen,Xiaoxia Qian,Dennis Feng,Jeffrey T. Kuethe,Giovanna Scapin,Ying-Duo Gao,Youwei Yan,Davida Krueger,Annette Bak,George J. Eiermann,Jiafang He,Jason M. Cox,Jacqueline D. Hicks,Kathy Lyons,Huaibing He,Gino Salituro,Sharon Tong,Sangita B. Patel,George A. Doss,Aleksandr Petrov,Joseph K. Wu,Shiyao Sherrie Xu,Charles Sewall,Xiaoping Zhang,Bei Zhang,Nancy A. Thornberry,Ann E. Weber +28 more
TL;DR: MK-3102 (omarigliptin), was identified as a potent and selective dipeptidyl peptidase 4 (DPP-4) inhibitor with an excellent pharmacokinetic profile amenable for once-weekly human dosing and selected as a clinical development candidate.
Journal ArticleDOI
Antidiabetic and antisteatotic effects of the selective fatty acid synthase (FAS) inhibitor platensimycin in mouse models of diabetes
Margaret Wu,Sheo B. Singh,Jun Wang,Christine C. Chung,Gino Salituro,Bindhu V. Karanam,Sang Ho Lee,Maryann Powles,Kenneth P. Ellsworth,Michael E. Lassman,Corey N. Miller,Robert W. Myers,Michael R. Tota,Bei B. Zhang,Cai Li +14 more
TL;DR: Chronic administration of platensimycin led to a net reduction in liver triglyceride levels and improved insulin sensitivity in db/+ mice fed a high-fructose diet, and PTM reduced ambient glucose levels in db/db mice.